Abstract: Chiral glutarimide stereochemical identity-preserving methods and compositions are disclosed. Also disclosed are methods of preparing chiral glutarimides stereoretentively.

Abstract: Methods of treating a BAF complex-related disorder, an SS18-SSX fusion protein-related disorder, a BRD9-related disorder, or cancer in a subject in need thereof are disclosed. The methods include the step of administering to the subject a regimen of an effective amount of compound S-D1 Compound S-DI, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are methods of administering the compound of formula (I) in a therapeutic regimen to a subject in need thereof, e.g., for treating cancer.

Abstract: The invention discloses a center lock structure, comprises a chassis, rotary sliding sleeve and a center rod, the top of the rotary sliding sleeve is circumferentially and slidely connected with the chassis; and the center rod is extended into the rotary sliding sleeve along the top of the chassis, an elastic member is provided at one side on the bottom of the center rod, the elastic member is exposed outside the center rod when there is no external force, and the elastic member is concealed in the center rod when squeezed by an external force; in the invention, by the center rod, upper and lower rotary sliding sleeve, through holes and the accommodating grooves for pressing or releasing the elastic member, the structure can be unlocked by rotation and pull-down.

Abstract: The invention discloses a center lock structure, comprises a chassis, rotary sliding sleeve and a center rod, the top of the rotary sliding sleeve is circumferentially and slidely connected with the chassis; and the center rod is extended into the rotary sliding sleeve along the top of the chassis, an elastic member is provided at one side on the bottom of the center rod, the elastic member is exposed outside the center rod when there is no external force, and the elastic member is concealed in the center rod when squeezed by an external force; in the invention, by the center rod, upper and lower rotary sliding sleeve, through holes and the accommodating grooves for pressing or releasing the elastic member, the structure can be unlocked by rotation and pull-down.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.

Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, R1d, R1e, R2, R3, R8a, R8b, L, X, Z1, and Z2 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Abstract: A method for cultivating perennial rice having perenniality using an asexual propagation characteristic of Oryza longistaminata, wherein a perennial rice carrying a perennial genetic locus of Oryza longistaminata and adapting to different ecological types is cultivated, which makes it possible to harvest for two or more years by means of planting only once, thereby increasing efficiency of rice cultivation and production.

Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.